UNSPSC 51172468: Dehydrocholic acid/pancreatin/pepsin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172468 Dehydrocholic acid/pancreatin/pepsin is a Commodity code that nominally describes a narrow pharmaceutical ingredient, but state and local procurement activity under this code bears little relevance to that product specification. The recent solicitations tagged with this code address drug testing services, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and over-the-counter products — categories that do not align with the enzymatic digestive-aid compound the code names. The mismatch suggests the code is either misapplied in state and local procurement systems or serves as a catch-all classification for pharmaceutical procurement activity that lacks a more precise code assignment.

The three most recent opportunities show activity across Texas and Minnesota, with issuing bodies spanning county criminal-justice agencies (Collin County Community Supervision and Corrections Department), state health authorities (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, which includes Oregon participation). Collin County posted RFP 2026-327 on July 9, 2026, seeking offender specimen collection and drug testing services with proposals due July 23, 2026, under a $600,000 estimated two-year contract commencing September 1, 2026. Texas HHS issued RFI HHS0017013 in late March 2026 to gather vendor intelligence on direct-to-manufacturer prescription programs before launching a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The code shows limited coherence as a targeting mechanism for pharmaceutical procurement; vendors pursuing state and local pharmaceutical work should rely on direct UNSPSC code verification with each issuing body rather than assume consistent application under this designation.